# A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct06628362` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06628362](<https://clinicaltrials.gov/study/NCT06628362>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06628362

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 447 participants.

## Technical summary

Registry record NCT06628362. Randomized; double masking; primary purpose treatment. Start 2024-11-21 (actual); primary completion 2026-05-29 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 447 participants (enrolled count; ClinicalTrials.gov record NCT06628362, source copy `cardio:ctgov-nct06628362-2026-10-28`, retrieved 2026-10-31)
- Started: 2024-11-21 (actual) (ClinicalTrials.gov record NCT06628362, source copy `cardio:ctgov-nct06628362-2026-10-28`, retrieved 2026-10-31)
- Primary completion: 2026-05-29 (actual) (ClinicalTrials.gov record NCT06628362, source copy `cardio:ctgov-nct06628362-2026-10-28`, retrieved 2026-10-31)
- Completion: 2026-10-02 (actual) (ClinicalTrials.gov record NCT06628362, source copy `cardio:ctgov-nct06628362-2026-10-28`, retrieved 2026-10-31)
- Countries: United States; Argentina; Canada; Mexico; New Zealand; Puerto Rico (ClinicalTrials.gov record NCT06628362, source copy `cardio:ctgov-nct06628362-2026-10-28`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06628362-2026-10-28`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus
- Condition: Overweight or Obese
- Condition: Type 2 Diabetes Mellitus (T2DM)
- Intervention (Drug): Placebo
- Intervention (Drug): Enicepatide
- Lead sponsor: Carmot Therapeutics, Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: Hoffmann-La Roche
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as a collaborator: Hoffmann-La Roche (`cardio:org-hoffmann-la-roche`)

## Provenance

Content hash: 0ace7b82133b92940b103adf4c826c57a66d866370fa5e482d0c06d5aafbc3ca
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
